APPLICATION NOTES

Three analytic studies were performed to evaluate the accuracy, precision, and reproducibility of the AIQ Software platform.

Early identification of both the benefits and the risks associated with immunotherapy are essential for the efficient development of effective therapies and will enable investigators to differentiate between patients who are likely to have an optimal vs. a sub-optimal response to therapy. This can impact the overall clinical outcome and reduce the number of severe or life-threatening adverse events, which are critical for guiding therapeutic management in the clinical setting.

By assessing patient treatment efficacy and toxicity risk earlier in theranostic therapy, investigators will be able to differentiate those patients who are likely to have an optimal vs. sub-optimal response. This information can impact the overall clinical outcome and reduce the number of severe or life-threatening adverse events, resulting in more efficient drug discovery timelines.